---
title: "Cardiac Arrhythmias"
order: 4
category: "Cardiology"
---

# Cardiac Arrhythmias

## Overview

Cardiac arrhythmias are abnormalities in the heart's electrical conduction system that result in irregular heart rhythms. They range from benign, asymptomatic rhythm disturbances to life-threatening conditions that can cause sudden cardiac death. Understanding the mechanisms, diagnosis, and management of arrhythmias is essential for all clinicians.

### Definition

An arrhythmia is any rhythm that deviates from normal sinus rhythm, characterized by:
- Normal sinus rhythm: Regular rhythm, 60-100 bpm, P wave before each QRS, consistent PR interval
- Arrhythmias: Abnormalities in rate, rhythm, origin of impulse, or conduction

### Classification

**By heart rate**:
- **Bradyarrhythmias**: Heart rate <60 bpm
- **Tachyarrhythmias**: Heart rate >100 bpm

**By site of origin**:
- **Supraventricular**: Atria, AV node (narrow QRS unless aberrancy)
- **Ventricular**: Ventricles, His-Purkinje system (wide QRS)

**By mechanism**:
- **Reentry**: Most common mechanism
- **Enhanced automaticity**: Abnormal spontaneous depolarization
- **Triggered activity**: Early or delayed afterdepolarizations

### Epidemiology

**Atrial fibrillation**:
- Most common sustained arrhythmia
- Prevalence: 2-4% of adults, increases with age (>10% at age >80)
- 3 million affected in United States

**Ventricular arrhythmias**:
- Premature ventricular contractions (PVCs): Common, often benign
- Ventricular tachycardia: Associated with structural heart disease
- Ventricular fibrillation: Leading cause of sudden cardiac death

**Supraventricular tachycardias**:
- AVNRT: Most common regular SVT
- Prevalence: 0.2-0.5% of population

## Pathophysiology

### Normal Cardiac Conduction

**Conduction system anatomy**:
1. **Sinoatrial (SA) node**: Pacemaker, spontaneous depolarization 60-100/min
2. **Internodal pathways**: Conduct impulse through atria
3. **Atrioventricular (AV) node**: Delays impulse 0.12-0.20 sec, allows ventricular filling
4. **Bundle of His**: Penetrates AV fibrous ring
5. **Bundle branches**: Right and left divisions
6. **Purkinje fibers**: Rapid conduction throughout ventricles

**Action potential**:
- **Phase 0** (depolarization): Rapid Na⁺ influx
- **Phase 1** (early repolarization): K⁺ efflux
- **Phase 2** (plateau): Ca²⁺ influx balanced by K⁺ efflux
- **Phase 3** (repolarization): K⁺ efflux
- **Phase 4** (resting): Na⁺/K⁺-ATPase maintains gradient

**Pacemaker cells** (SA node, AV node):
- Phase 4: Spontaneous depolarization (funny current If, T-type Ca²⁺ channels)
- No stable resting potential
- Automaticity: Intrinsic rates (SA node 60-100, AV node 40-60, Purkinje 20-40)

### Mechanisms of Arrhythmias

**Reentry**:

*Requirements*:
1. Circuit with two or more pathways
2. Unidirectional block in one pathway
3. Slow conduction allowing recovery in blocked pathway
4. Wavelength (conduction velocity × refractory period) less than circuit length

*Types*:
- **Anatomic reentry**: Fixed circuit (e.g., AVRT in WPW, atrial flutter)
- **Functional reentry**: Dynamic circuit without anatomic obstacle (e.g., AF, VF)

*Examples*:
- AVNRT: Dual AV nodal pathways (fast and slow)
- AVRT: Accessory pathway (WPW syndrome)
- Atrial flutter: Cavotricuspid isthmus circuit
- VT: Scar tissue creates reentry circuit

**Abnormal automaticity**:
- Increased phase 4 slope (enhanced spontaneous depolarization)
- Non-pacemaker cells develop automaticity
- Ectopic pacemaker overrides SA node

*Causes*:
- Ischemia, hypoxia
- Electrolyte abnormalities (hypokalemia)
- Catecholamines, digitalis
- Stretch (atrial dilatation)

*Examples*:
- Sinus tachycardia
- Atrial tachycardia
- Accelerated idioventricular rhythm
- Some VT

**Triggered activity**:

*Early afterdepolarizations (EADs)*:
- Occur during phase 2 or 3 (before full repolarization)
- Due to prolonged action potential duration (long QT)
- Can trigger torsades de pointes

*Delayed afterdepolarizations (DADs)*:
- Occur after complete repolarization (phase 4)
- Due to intracellular calcium overload
- Triggered by catecholamines, digitalis toxicity

## Bradyarrhythmias

### Sinus Node Dysfunction

**Types**:
- **Sinus bradycardia**: Sinus rhythm <60 bpm
- **Sinus pause/arrest**: Absence of P waves, pause not multiple of P-P interval
- **Sinoatrial exit block**: Pause is multiple of P-P interval
- **Tachy-brady syndrome**: Alternating tachycardia and bradycardia

**Etiology**:
- **Intrinsic**: Idiopathic fibrosis, ischemia, infiltrative disease (amyloid, sarcoid)
- **Extrinsic**: Medications (beta-blockers, calcium channel blockers, digoxin), hypothyroidism, increased vagal tone

**Clinical presentation**:
- Asymptomatic (common in athletes)
- Fatigue, exercise intolerance
- Dizziness, presyncope, syncope
- Worsening heart failure

**Diagnosis**:
- ECG: Bradycardia, pauses, evidence of tachy-brady
- Ambulatory monitoring: Correlate symptoms with rhythm
- Exercise testing: Chronotropic incompetence (failure to increase HR with exercise)

**Treatment**:
- **Asymptomatic**: No treatment
- **Symptomatic**: Permanent pacemaker (Class I if symptomatic)
- Withdraw offending medications if possible

### Atrioventricular Block

**First-degree AV block**:
- PR interval >200 ms
- Every P wave conducted
- Usually benign, no treatment required

**Second-degree AV block**:

*Mobitz Type I (Wenckebach)*:
- Progressive PR prolongation until dropped QRS
- AV nodal disease
- Usually benign, pacing rarely needed
- Can occur in increased vagal tone (athletes, sleep)

*Mobitz Type II*:
- Fixed PR interval with intermittent dropped QRS
- Infranodal disease (His-Purkinje system)
- Risk of progression to complete heart block
- Pacemaker indicated

**Third-degree (complete) AV block**:
- No atrial impulses conducted to ventricles
- Independent atrial and ventricular rhythms (AV dissociation)
- Escape rhythm: Junctional (40-60 bpm, narrow QRS) or ventricular (20-40 bpm, wide QRS)
- Causes: Ischemia (especially inferior MI), fibrosis, medications, Lyme disease
- Treatment: Temporary then permanent pacemaker

**2:1 AV block**:
- Every other P wave conducted
- Cannot distinguish Type I vs. Type II
- Infranodal if wide QRS → pacemaker

### Pacemaker Therapy

**Indications (Class I)**:
- Third-degree or advanced second-degree AV block, symptomatic
- Second-degree Mobitz II AV block
- Symptomatic sinus node dysfunction
- Chronic bifascicular/trifascicular block with intermittent third-degree block

**Pacing modes (NBG code)**:
- **AAI**: Atrial pacing and sensing, inhibited by sensed event
- **VVI**: Ventricular pacing and sensing, inhibited
- **DDD**: Dual chamber pacing and sensing, dual response (physiologic)
- R: Rate modulation (responds to activity)

**Complications**:
- Lead displacement or fracture
- Infection (pocket, endocarditis)
- Pneumothorax (during implantation)
- Pacemaker syndrome (AV dyssynchrony with VVI pacing)
- Venous thrombosis
- Electromagnetic interference

## Supraventricular Tachycardias

### Atrial Fibrillation

**Definition**:
- Disorganized atrial electrical activity
- Irregularly irregular ventricular response
- Absence of discrete P waves

**Classification**:
- **Paroxysmal**: Self-terminating within 7 days (usually <48 hours)
- **Persistent**: Lasting >7 days or requiring cardioversion
- **Long-standing persistent**: >12 months
- **Permanent**: Accepted, no further rhythm control attempts

**Epidemiology**:
- Most common sustained arrhythmia
- 2-4% prevalence, increases with age
- Lifetime risk: 25% at age 40

**Risk factors**:
- Age (strongest predictor)
- Hypertension
- Heart failure
- Valvular heart disease (especially mitral)
- Cardiomyopathy
- Coronary artery disease
- Hyperthyroidism
- Obesity, diabetes
- Alcohol ("holiday heart syndrome")
- Sleep apnea

**Pathophysiology**:
- Multiple reentrant wavelets in atria
- Trigger: Often ectopic foci from pulmonary veins
- Substrate: Atrial fibrosis, dilatation
- Rapid atrial rate (400-600/min)
- Variable AV node conduction → irregular ventricular response

**Clinical presentation**:
- Asymptomatic (common)
- Palpitations
- Dyspnea, fatigue, exercise intolerance
- Chest discomfort
- Lightheadedness, syncope
- Heart failure exacerbation
- Stroke (embolic)

**Diagnosis**:
- **ECG**: Irregularly irregular rhythm, absence of P waves, fibrillatory waves
- **Ambulatory monitoring**: If paroxysmal
- **Echocardiogram**: Assess structural disease, LA size, LV function, thrombus
- **Labs**: TSH, electrolytes

**Complications**:
- **Thromboembolism**: Stroke risk 5%/year untreated
- **Heart failure**: Loss of atrial kick, tachycardia-induced cardiomyopathy
- **Hemodynamic instability**: Especially in severe AS, HCM, HFrEF

**Treatment**:

*Acute management*:
- **Hemodynamically unstable**: Immediate electrical cardioversion
- **Stable**: Rate control or rhythm control strategy

*Rate control*:
- Target: Resting HR <110 bpm (lenient) or <80 bpm (strict)
- **Beta-blockers**: Metoprolol, esmolol (first-line)
- **Calcium channel blockers**: Diltiazem, verapamil (avoid in HFrEF)
- **Digoxin**: Less effective, useful in HFrEF
- **Amiodarone**: If other agents contraindicated or ineffective

*Rhythm control*:
- **Electrical cardioversion**: If onset <48 hours or anticoagulated ≥3 weeks
- **Pharmacologic cardioversion**:
  - Flecainide, propafenone (no structural heart disease)
  - Amiodarone (structural heart disease)
  - Ibutilide (IV, acute setting)
- **Catheter ablation**: Pulmonary vein isolation
  - First-line in selected patients (young, symptomatic, paroxysmal)
  - Success rate 60-80% after single procedure

*Anticoagulation* (stroke prevention):
- **Risk stratification**: CHA₂DS₂-VASc score
  - C: CHF (1 point)
  - H: Hypertension (1)
  - A₂: Age ≥75 (2)
  - D: Diabetes (1)
  - S₂: Stroke/TIA/thromboembolism (2)
  - V: Vascular disease (1)
  - A: Age 65-74 (1)
  - Sc: Sex category female (1)

- **Anticoagulation recommendations**:
  - Score 0 (men) or 1 (women): No anticoagulation or aspirin
  - Score 1 (men) or 2 (women): Consider anticoagulation
  - Score ≥2 (men) or ≥3 (women): Anticoagulation recommended

- **Options**:
  - **DOACs** (preferred): Apixaban, rivaroxaban, edoxaban, dabigatran
  - **Warfarin**: Target INR 2-3
  - **Aspirin**: Inferior to anticoagulation, not recommended

- **Left atrial appendage closure**: For patients with contraindication to anticoagulation (Watchman device)

### Atrial Flutter

**Definition**:
- Macro-reentrant atrial tachycardia
- Regular atrial rate, typically 250-350 bpm
- Sawtooth flutter waves

**Types**:
- **Typical (isthmus-dependent)**: Cavotricuspid isthmus circuit
  - Counterclockwise: Negative flutter waves in inferior leads
  - Clockwise: Positive flutter waves in inferior leads
- **Atypical (non-isthmus-dependent)**: Other circuits, often post-cardiac surgery

**Clinical presentation**:
- Similar to atrial fibrillation
- More likely to have regular ventricular response (2:1, 3:1, 4:1 conduction)

**Diagnosis**:
- **ECG**: Regular sawtooth flutter waves, no isoelectric baseline in leads II, III, aVF
- Ventricular rate often 150 bpm (2:1 conduction with atrial rate 300 bpm)

**Treatment**:
- Similar principles to atrial fibrillation
- **Rate control**: Same agents as AF
- **Rhythm control**:
  - Electrical cardioversion: Low threshold (50-100 J often sufficient)
  - Pharmacologic: Less effective than in AF
- **Catheter ablation**: Cavotricuspid isthmus ablation (>90% success for typical flutter)
- **Anticoagulation**: Same as atrial fibrillation (similar stroke risk)

### Paroxysmal Supraventricular Tachycardia (PSVT)

**Atrioventricular nodal reentrant tachycardia (AVNRT)**:

*Mechanism*:
- Reentry within AV node using dual pathways (slow and fast)
- **Typical (slow-fast)**: Anterograde slow, retrograde fast
- **Atypical (fast-slow)**: Anterograde fast, retrograde slow

*ECG*:
- Regular narrow complex tachycardia, 140-250 bpm
- Typical: Pseudo R' in V1, pseudo S in inferior leads (retrograde P buried in QRS)
- Atypical: Long RP interval (P after QRS)

*Clinical presentation*:
- Sudden onset and termination
- Palpitations, lightheadedness, dyspnea, chest discomfort
- Polyuria (atrial stretch → ANP release)

*Acute treatment*:
- **Vagal maneuvers**: Valsalva, carotid massage, cold water immersion
- **Adenosine**: 6 mg IV rapid push, then 12 mg if needed (blocks AV node, terminates >90%)
- **Calcium channel blockers or beta-blockers**: If adenosine fails
- **Cardioversion**: If hemodynamically unstable

*Long-term management*:
- **Observation**: If infrequent, well-tolerated
- **AV nodal blocking agents**: Beta-blockers, calcium channel blockers (prevent recurrence)
- **Catheter ablation**: Curative, >95% success, <1% risk of complete heart block

**Atrioventricular reentrant tachycardia (AVRT)**:

*Mechanism*:
- Accessory pathway connects atria and ventricles, bypassing AV node
- **Wolff-Parkinson-White (WPW) syndrome**: Manifest accessory pathway
  - Anterograde conduction over pathway: Short PR, delta wave, wide QRS
  - Risk of rapid conduction in AF → VF
- **Orthodromic AVRT** (95%): Anterograde AV node, retrograde accessory pathway → narrow QRS
- **Antidromic AVRT** (5%): Anterograde accessory pathway, retrograde AV node → wide QRS

*ECG*:
- **Sinus rhythm with WPW**: Short PR (<120 ms), delta wave, wide QRS
- **Orthodromic AVRT**: Regular narrow complex tachycardia, P wave after QRS (RP <PR)
- **Antidromic AVRT**: Regular wide complex tachycardia

*Acute treatment*:
- **Orthodromic AVRT**: Same as AVNRT (vagal, adenosine, cardioversion)
- **Antidromic AVRT or AF with WPW**:
  - AVOID AV nodal blockers (adenosine, beta-blockers, CCBs, digoxin) → can increase ventricular rate
  - **Procainamide or ibutilide**: Slow accessory pathway conduction
  - **Cardioversion**: If unstable

*Long-term management*:
- **Asymptomatic WPW pattern**: Risk stratification (EP study, exercise test)
- **Symptomatic AVRT**: Catheter ablation (>95% success, <1% complication)
- **High-risk occupation (pilots)**: Consider prophylactic ablation

**Focal atrial tachycardia**:

*Mechanism*:
- Abnormal automaticity or triggered activity
- Ectopic focus (often pulmonary veins, crista terminalis)

*ECG*:
- Regular narrow complex tachycardia
- P wave morphology different from sinus
- RP > PR (long RP tachycardia)
- Warm-up and cool-down

*Treatment*:
- **Acute**: Beta-blockers, calcium channel blockers
- **Chronic**: Ablation of ectopic focus

**Multifocal atrial tachycardia (MAT)**:

*Mechanism*:
- Multiple ectopic atrial foci
- Associated with severe lung disease (COPD), hypoxia

*ECG*:
- Irregularly irregular rhythm (mimics AF)
- ≥3 different P wave morphologies
- Varying PR intervals

*Treatment*:
- Treat underlying disease (COPD, hypoxia)
- Magnesium supplementation
- Verapamil or metoprolol if hemodynamically tolerated

## Ventricular Arrhythmias

### Premature Ventricular Contractions (PVCs)

**Definition**:
- Premature beats originating from ventricles
- Wide QRS (>120 ms), not preceded by P wave

**Patterns**:
- **Bigeminy**: Every other beat is PVC
- **Trigeminy**: Every third beat is PVC
- **Couplet**: Two consecutive PVCs
- **Triplet/non-sustained VT**: Three or more consecutive PVCs

**Etiology**:
- Idiopathic (structurally normal heart)
- Ischemic heart disease, cardiomyopathy
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Stimulants (caffeine, cocaine, amphetamines)
- Medications (digoxin toxicity)

**Clinical significance**:
- Usually benign if no structural heart disease
- Frequent PVCs (>10,000-15,000/day) can cause cardiomyopathy
- High PVC burden post-MI associated with increased mortality

**Treatment**:
- **No structural heart disease + asymptomatic**: Reassurance, no treatment
- **Symptomatic**: Beta-blockers
- **PVC-induced cardiomyopathy**: Catheter ablation
- Avoid triggers (caffeine, alcohol, stress)

### Ventricular Tachycardia (VT)

**Definition**:
- Three or more consecutive ventricular beats at rate >100 bpm
- **Non-sustained VT (NSVT)**: <30 seconds
- **Sustained VT**: ≥30 seconds or hemodynamically significant

**Types**:

*Monomorphic VT*:
- Uniform QRS morphology
- Usually scar-related reentry (post-MI, cardiomyopathy)
- Hemodynamically variable

*Polymorphic VT*:
- Varying QRS morphology
- **Normal QT**: Acute ischemia, structural heart disease
- **Long QT**: Torsades de pointes (see below)

**ECG features suggesting VT** (vs. SVT with aberrancy):
- AV dissociation (P waves and QRS independent)
- Capture or fusion beats
- Very wide QRS (>140 ms)
- Extreme axis deviation
- Absence of RS complex in precordial leads
- Brugada criteria, Vereckei algorithm

**Clinical presentation**:
- Palpitations, dizziness, dyspnea, chest pain
- Syncope
- Hemodynamic collapse
- Sudden cardiac death

**Acute management**:

*Hemodynamically unstable*:
- Immediate synchronized cardioversion (100-200 J biphasic)
- CPR if pulseless VT

*Hemodynamically stable*:
- **Monomorphic VT**: Amiodarone 150 mg IV over 10 min, then infusion
  - Alternatives: Procainamide, lidocaine, sotalol
- **Polymorphic VT with normal QT**: Treat ischemia, beta-blockers, amiodarone
- **Torsades de pointes**: Magnesium 2g IV, correct electrolytes, increase HR (pacing, isoproterenol), discontinue QT-prolonging drugs

*Long-term management*:
- Identify and treat underlying cause
- **ICD**: Primary or secondary prevention of sudden death
- **Antiarrhythmic drugs**: Amiodarone, sotalol (adjunct to ICD)
- **Catheter ablation**: Scar-related VT, frequent ICD shocks

**Specific VT syndromes**:

*Idiopathic VT*:
- Structurally normal heart
- **RVOT VT**: LBBB morphology, inferior axis, triggered by exercise
- **Fascicular VT**: RBBB morphology, superior axis, verapamil-sensitive
- Excellent prognosis, amenable to ablation

*Bundle branch reentrant VT*:
- Dilated cardiomyopathy with conduction disease
- LBBB or RBBB morphology
- Ablation of right bundle branch curative

### Ventricular Fibrillation (VF)

**Definition**:
- Chaotic ventricular electrical activity
- No organized QRS complexes
- No effective cardiac output

**Causes**:
- Acute MI (most common)
- Cardiomyopathy
- Electrolyte abnormalities
- Long QT syndrome, Brugada syndrome
- Commotio cordis (chest wall trauma)

**Treatment**:
- **Immediate CPR and defibrillation** (unsynchronized, 200 J biphasic)
- ACLS protocol
- **Survivors**: ICD for secondary prevention
- Treat reversible causes

### Torsades de Pointes

**Definition**:
- Polymorphic VT with "twisting of the points"
- Associated with prolonged QT interval

**Causes of long QT**:

*Congenital*:
- Long QT syndrome (LQTS): Channelopathies (KCNQ1, KCNH2, SCN5A)
- Romano-Ward (autosomal dominant)
- Jervell and Lange-Nielsen (autosomal recessive, with deafness)

*Acquired*:
- **Medications**: Antiarrhythmics (Class IA, III), antibiotics (macrolides, fluoroquinolones), antipsychotics, antidepressants
- **Electrolyte abnormalities**: Hypokalemia, hypomagnesemia, hypocalcemia
- **Bradycardia**
- **Intracranial pathology**: Subarachnoid hemorrhage

**Triggers**:
- LQT1: Exercise (swimming)
- LQT2: Sudden arousal (alarm clock)
- LQT3: Sleep, rest

**Treatment**:
- **Acute**: Magnesium 2 g IV bolus (even if normal Mg), correct electrolytes
- **Increase heart rate**: Isoproterenol infusion, temporary pacing (shortens QT)
- **Remove offending agent**
- **Congenital LQTS**:
  - Beta-blockers (all patients)
  - ICD (if high risk: prior cardiac arrest, recurrent syncope on beta-blockers)
  - Left cardiac sympathetic denervation

## Inherited Arrhythmia Syndromes

### Brugada Syndrome

**Genetics**:
- Autosomal dominant
- Sodium channel mutation (SCN5A, 20-30% of cases)
- Predominantly affects males

**ECG patterns**:
- **Type 1** (diagnostic): Coved ST elevation ≥2 mm in V1-V2, followed by negative T wave
- **Type 2 and 3**: Saddle-back pattern (less specific)
- Dynamic (may be unmasked by fever, sodium channel blockers)

**Clinical presentation**:
- Syncope, sudden cardiac death (VF)
- Typically occurs at rest or sleep
- Often first presentation in 3rd-4th decade

**Diagnosis**:
- Type 1 ECG pattern (spontaneous or drug-induced with ajmaline, flecainide, procainamide)
- Family history, genetic testing

**Treatment**:
- **ICD**: Only proven therapy
- Indications: Survivors of cardiac arrest, syncope with Type 1 ECG
- Avoid triggers: Fever (treat aggressively), certain drugs (extensive list)
- Isoproterenol or quinidine for VF storm

### Catecholaminergic Polymorphic VT (CPVT)

**Genetics**:
- Mutations in ryanodine receptor (RyR2) or calsequestrin (CASQ2)
- Abnormal calcium handling

**Clinical presentation**:
- Exercise or emotion-induced syncope
- Typically in children or adolescents
- Family history of sudden death

**ECG**:
- Normal at rest
- Bidirectional VT with exercise (alternating QRS axis)
- Polymorphic VT, VF

**Treatment**:
- **Beta-blockers**: High-dose (nadolol, propranolol)
- **ICD**: If high risk (prior cardiac arrest, syncope despite beta-blockers)
- Flecainide: Adjunct therapy
- Left cardiac sympathetic denervation
- Avoid competitive sports, strenuous exercise

### Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

**Pathophysiology**:
- Fibrofatty replacement of RV myocardium
- Desmosmal protein mutations
- Substrate for ventricular arrhythmias

**Clinical presentation**:
- Palpitations, syncope, sudden cardiac death
- Young athletes
- Heart failure (advanced disease)

**Diagnosis (Task Force Criteria)**:
- ECG: T wave inversion V1-V3, epsilon wave (late potential), incomplete RBBB
- Imaging: RV dilatation, dyskinesia, aneurysm (MRI gold standard)
- Arrhythmias: VT with LBBB morphology
- Family history, genetic testing
- Endomyocardial biopsy: Fibrofatty replacement

**Treatment**:
- **ICD**: High risk for sudden death
- **Antiarrhythmic drugs**: Sotalol, amiodarone
- **Catheter ablation**: Adjunct for VT
- Avoid strenuous exercise, competitive sports
- Heart transplantation for end-stage disease

## Antiarrhythmic Drugs

### Vaughan Williams Classification

**Class I: Sodium channel blockers**

*Class IA* (moderate sodium block, prolongs APD):
- Quinidine, procainamide, disopyramide
- Indications: VT, AF (limited use now)
- Side effects: Torsades, hypotension, GI upset
- Procainamide: Lupus-like syndrome

*Class IB* (weak sodium block, shortens APD):
- Lidocaine, mexiletine
- Indications: VT (acute setting)
- Side effects: CNS toxicity (seizures, altered mental status)

*Class IC* (strong sodium block, no APD change):
- Flecainide, propafenone
- Indications: AF, SVT (no structural heart disease)
- Contraindications: Ischemic heart disease, LV dysfunction (CAST trial: increased mortality)
- Side effects: Proarrhythmia, bradycardia

**Class II: Beta-blockers**
- Metoprolol, esmolol, propranolol, sotalol (also Class III)
- Indications: SVT (rate control), VT, AF, post-MI
- Mechanism: Reduce sympathetic stimulation, slow AV node
- Side effects: Bradycardia, hypotension, bronchospasm

**Class III: Potassium channel blockers (prolong APD)**

*Amiodarone*:
- Most effective antiarrhythmic
- Indications: AF, VT, SVT
- Unique pharmacokinetics: Large volume of distribution, long half-life (weeks)
- Side effects: Pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, corneal deposits, blue-gray skin discoloration, bradycardia, torsades (rare)
- Requires monitoring: Baseline and periodic PFTs, LFTs, TFTs, ophthalmology exam

*Sotalol*:
- Beta-blocker + Class III properties
- Indications: AF, VT
- Side effects: Torsades (dose-related, 2-5%), bradycardia
- Renally cleared: Dose adjustment required
- Contraindications: Long QT, severe renal impairment

*Dofetilide*:
- Pure potassium channel blocker
- Indications: AF
- High efficacy for cardioversion and maintenance of sinus rhythm
- Requires in-hospital initiation (3 days): High risk of torsades
- Renally cleared: Dose based on CrCl
- Contraindications: Long QT, severe renal impairment

*Ibutilide*:
- IV only, short-acting
- Indications: Acute cardioversion of AF/flutter
- Side effects: Torsades (4-8%)

**Class IV: Calcium channel blockers**
- Diltiazem, verapamil
- Indications: SVT (rate control), AF rate control
- Mechanism: Slow AV node conduction
- Contraindications: LV dysfunction, WPW with AF
- Side effects: Hypotension, bradycardia, constipation

**Other antiarrhythmics**:

*Adenosine*:
- Very short half-life (<10 sec)
- Indications: Acute termination of AVNRT, AVRT; diagnostic tool
- Dose: 6 mg rapid IV push, then 12 mg × 2 if needed
- Side effects: Flushing, chest discomfort, dyspnea, bronchospasm (transient)
- Contraindications: Asthma, second/third-degree AV block, WPW with AF

*Digoxin*:
- Enhances vagal tone, slows AV node
- Indications: AF rate control (especially with HFrEF), SVT
- Narrow therapeutic window
- Toxicity: Arrhythmias (PAT with block, VT, AV block), GI symptoms, visual changes
- Factors increasing toxicity: Hypokalemia, hypomagnesemia, renal dysfunction

## Sudden Cardiac Death

**Definition**:
- Unexpected death from cardiac cause within 1 hour of symptom onset
- Most commonly from ventricular arrhythmias (VT/VF)

**Epidemiology**:
- 300,000-400,000 cases annually in United States
- Leading cause of death in athletes
- Accounts for 50% of cardiac deaths

**Etiologies**:

*Structural heart disease*:
- Coronary artery disease (80% of SCD in adults >35 years)
- Cardiomyopathy (dilated, hypertrophic, ARVC)
- Valvular heart disease
- Congenital heart disease

*Primary electrical disease*:
- Long QT syndrome
- Brugada syndrome
- CPVT
- Short QT syndrome
- Early repolarization syndrome
- Idiopathic VF

*Other*:
- Commotio cordis (chest wall trauma)
- Electrolyte abnormalities
- Drugs (proarrhythmic, illicit)

**Primary prevention**:

*ICD indications*:
- Ischemic cardiomyopathy: EF ≤35%, >40 days post-MI
- Non-ischemic cardiomyopathy: EF ≤35%, NYHA II-III
- Hypertrophic cardiomyopathy: High-risk features
- Congenital channelopathies: High-risk features

*Other measures*:
- Beta-blockers post-MI
- Optimal medical therapy for heart failure
- Revascularization for ischemic disease
- Genetic counseling and family screening

**Secondary prevention**:
- ICD for survivors of cardiac arrest (no reversible cause)

**Resuscitation**:
- Immediate CPR
- Early defibrillation (PAD programs)
- ACLS protocol
- Post-arrest care: Targeted temperature management, PCI if STEMI

## Key Points

- Arrhythmias result from abnormalities in impulse formation (automaticity, triggered activity) or conduction (reentry)
- Atrial fibrillation is the most common sustained arrhythmia; anticoagulation reduces stroke risk based on CHA₂DS₂-VASc score
- Hemodynamically unstable tachyarrhythmias require immediate cardioversion
- AVNRT is the most common regular SVT; catheter ablation is curative with >95% success
- Ventricular arrhythmias in structural heart disease carry high risk of sudden death; ICD is primary therapy
- Inherited arrhythmia syndromes (long QT, Brugada, CPVT) require specific management and family screening
- Antiarrhythmic drugs are classified by Vaughan Williams system; many have proarrhythmic effects
- ICD therapy is indicated for primary and secondary prevention of sudden cardiac death in selected patients

## References

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018;138(13):e272-e391.

2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.

3. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020;41(5):655-720.

4. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. Circulation. 2019;140(8):e382-e482.

5. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867.

6. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8(8):1308-1339.

7. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.

8. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016;133(14):e506-e574.

9. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114(10):e385-e484.

10. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11(10):e166-e196.
